E-MTAB-7349
Ontology highlight
ABSTRACT:
PROVIDER: E-MTAB-7349 | ExpressionAtlas | 2019-01-16
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-MTAB-7349-analysis-methods.tsv | Tabular | |||
| E-MTAB-7349-analytics.tsv | Tabular | |||
| E-MTAB-7349-atlasExperimentSummary.Rdata | Rdata | |||
| E-MTAB-7349-configuration.xml | Xml | |||
| E-MTAB-7349-g2_g1-mvaPlot.png | Other |
Items per page: 5 1 - 5 of 22 |
Similar Datasets
Project description:Receptor Tyrosine Kinase pathway activation is sufficient to trigger chordoma in zebrafish
| PRJEB29441 | ENA
Project description:Receptor Tyrosine Kinase Activation in Infantile Fibrosarcoma/Congenital Mesoblastic Nephroma
| PRJNA146253 | ENA
Project description:Glucocorticoid-resistant B-cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
| PRJEB31697 | ENA
Project description:Oncogenic transformation of individual cell fates by developmental signaling cascades and transcription factors triggers diverse cancer types. Chordoma is a rare, aggressive tumor arising from transformed notochord remnants. Various potentially oncogenic factors have been found deregulated in chordoma and its metastases, yet clear causation remains uncertain. In particular, expression of the notochord-controlling transcription factor Brachyury is hypothesized as key molecular driver in chordoma formation, yet an in vivo model to causally test its oncogenic potential in the notochord is missing. Here, we apply a zebrafish model of chordoma onset to identify the notochord-transforming potential of tumor-implicated candidate genes in vivo. We find that overexpression of human and zebrafish Brachyury, including a version with augmented transcriptional activity, is insufficient to initiate notochord hyperplasia in vivo. In contrast, the repeatedly chordoma-implicated receptor tyrosine kinase (RTK) genes EGFR and KDR/VEGFR2 are sufficient to transform developmental notochord cells, akin to direct activation of Ras. Analysis of transcriptome and sub-cellular organization from transformed notochords suggests that aberrant activation of RTK/Ras signaling attenuates processes required for the differentiation of notochord cells. Taken together, our results provide first in vivo indication for a lack of tumor-initiating potential of Brachyury expression in the notochord, and suggest activated RTK signaling as potent hyperplasia-initiating event in chordoma.
2018-12-01 | E-MTAB-7349 | biostudies-arrayexpress
Project description:The type III receptor tyrosine kinase, FLT3 is frequently mutated in acute myeloid leukemia. Phosphorylation of FLT3 on tyrosine residues is a critical event for downstream signaling. Here we studied the role of Y842 residue of FLT3, which is located in the activation loop.
2017-05-02 | E-MTAB-5258 | biostudies-arrayexpress
Project description:Hepatocyte growth factor (HGF) signaling through its receptor Met has been implicated in hepatocellular carcinoma tumorigenesis and progression. Met interaction with integrins is shown to modulate the downstream signaling to Akt and ERK (extracellular-regulated kinase). In this study, we developed a mechanistically detailed systems biology model of HGF/Met signaling pathway that incorporated specific interactions with integrins to investigate the efficacy of integrin-binding peptide, AXT050, as monotherapy and in combination with other therapeutics targeting this pathway. Here we report that the modeled dynamics of the response to AXT050 revealed that receptor trafficking is sufficient to explain the effect of Met-integrin interactions on HGF signaling. Furthermore, the model predicted patient-specific synergy and antagonism of efficacy and potency for combination of AXT050 with sorafenib, cabozantinib, and rilotumumab. Overall, the model provides a valuable framework for studying the efficacy of drugs targeting receptor tyrosine kinase interaction with integrins, and identification of synergistic drug combinations for the patients.
Model is encoded by Johannes and submitted to BioModels by Ahmad Zyoud.
2020-03-20 | MODEL2003200001 | BioModels
Project description:Muscle-specific receptor tyrosine kinase (MuSK) agonist antibodies were developed two decades ago to explore the benefits of receptor activation at the neuromuscular junction. Unlike agrin, the endogenous agonist of MuSK, MuSK agonist antibodies function independently of its co-receptor Lrp4. Recent reports suggest that MuSK agonist antibodies can delay the onset of muscle denervation in mouse models of amyotrophic lateral sclerosis (ALS). To get a deeper understanding of MuSK signaling, and potentially identify Lrp4-independent signaling downstream of MuSK activation, we performed phosphoproteome profiling of myotubes treated with each agonist. Our approach involved quantifying changes in site-specific phosphorylation in orthogonal dose response and time course experiments with each agonist using isobaric mass tags. We observed that both agonists elicited remarkably similar intracellular responses, as evidenced by highly correlating tyrosine phosphorylation on known MuSK signaling components and newly identified cytoskeletal and intracellular trafficking nodes. Among these was inducible phosphorylation on a conserved N-terminal phosphorylation site present on a family of endosomal Rab GTPases. We confirmed that suppression of MuSK signaling by a small molecule reduces Rab10 tyrosine phosphorylation. Importantly, Rab10 mutation at this site disrupts its association with adaptor molecules Mical1 and Mical3. Together these data provide an in depth characterization of the MuSK signaling pathway, describe two small molecule kinase inhibitors, and reveal a novel regulatory mechanism of small Rab GTPases that is poised to regulate intracellular trafficking downstream of receptor tyrosine kinase activation.
2020-06-04 | MSV000085547 | MassIVE
Project description:Phosphoinositide-3-kinase (PI3K)-α inhibitors are clinically active in squamous carcinoma (SCC) of the head and neck (H&N) bearing mutations or amplification of PIK3CA. We aimed to identify potential mechanism of resistance and have observed that SCCs cells overcome the antitumor effects of the PI3Kα inhibitor BYL719 by maintaining PI3K-independent activation of the mammalian target of rapamycin (mTOR). The persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. We found that AXL is overexpressed in resistant tumors, dimerizes with the epidermal growth factor receptor (EGFR), phosphorylates EGFR tyrosine 1173, resulting in activation of phospholipase Cγ (PLCγ)- protein kinase C (PKC) that, in turn, activates mTOR. Finally, simultaneous treatment with PI3Kα and either EGFR, AXL or PKC inhibitors reverts this resistance. RNAseq from acquired resistant cells CAL33B, K180B were compared to their parental counterpart CAL33 and K180, respectively. K180 is a shortcut of KYSE180, and B stands for BYL719. Duplicate of parental sensitive cells and K180B, and triplicate for CAL33B.
2015-04-12 | E-GEOD-61515 | biostudies-arrayexpress
Project description:Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a cytosolic protein kinase that regulates multiple inflammatory and cell death pathways. Serine/Threonine phosphorylation of RIPK1 is known to suppress RIPK1 kinase-mediated cell death in the contexts of inflammation, infection and embryogenesis, however, regulation by tyrosine phosphorylation has not been reported. Here, we show that non-receptor tyrosine kinases Janus kinase 1 (JAK1) and SRC are able to phosphorylate RIPK1 at Y384 (Y383 in murine RIPK1), leading to suppression of TNF-induced cell death. Mice bearing a homozygous Ripk1 mutation that prevents tyrosine phosphorylation of RIPK1 (Ripk1Y383F/Y383F), develop systemic inflammation and emergency haematopoiesis. Mechanistically, Ripk1Y383F/Y383F mutation promotes RIPK1 kinase activation and enhances TNF-induced apoptosis and necroptosis, which is partially due to impaired recruitment and activation of MAP kinase-activated protein kinase 2 (MK2). The systemic inflammation and emergency haematopoiesis in Ripk1Y383F/Y383F mice are largely alleviated by RIPK1 kinase inhibition, and prevented by genomic deletions targeted to the upstream pathway (either to Tumor necrosis factor receptor 1 or RIPK3 and Caspase8 simultaneously). In summary, our results demonstrate that tyrosine phosphorylation of RIPK1 is critical for regulating RIPK1 activity to limit cell death and inflammation.
2022-10-12 | PXD036995 | Pride
Project description:<p>The genetic basis of hypodiploid acute lymphoblastic leukemia (ALL), a subtype of ALL characterized by aneuploidy and poor outcome, is unknown. Genomic profiling of 124 hypodiploid ALL cases, including whole-genome and exome sequencing of 40 cases, identified two subtypes that differ in the severity of aneuploidy, transcriptional profiles and submicroscopic genetic alterations. Near-haploid ALL with 24-31 chromosomes harbor alterations targeting receptor tyrosine kinase signaling and Ras signaling (71%) and the lymphoid transcription factor gene IKZF3 (encoding AIOLOS; 13%). In contrast, low-hypodiploid ALL with 32-39 chromosomes are characterized by alterations in TP53 (91.2%) that are commonly present in nontumor cells, IKZF2 (encoding HELIOS; 53%) and RB1 (41%). Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase (PI3K)-signaling pathways and are sensitive to PI3K inhibitors, indicating that these drugs should be explored as a new therapeutic strategy for this aggressive form of leukemia.</p>
| phs000341 | dbGaP